Future research should focus on elucidating the specificity of IgA antibodies, their impact on RBC morphology, and exact mechanism of RBC destruction, as well as the long‐term outcomes of novel therapeutic strategies like bortezomib in AIHA cases. This evidence concerns the gene CD79A and autoimmune hemolytic anemia.